Clinical Research

Clinical Orthopaedics and Related Research®

, Volume 468, Issue 3, pp 834-845

First online:

Results of 32 Allograft-prosthesis Composite Reconstructions of the Proximal Femur

  • David J. BiauAffiliated withDepartment of Orthopaedic Surgery, Hôpital Cochin, Université Paris DescartesDepartment of Biostatistics and Clinical Epidemiology, Hôpital Saint Louis, INSERM–UMR-S 717, Université Paris Diderot, AP-HP Email author 
  • , Frédérique LarousserieAffiliated withDepartment of Pathology, Hôpital Cochin, Université Paris Descartes, AP-HP
  • , Fabrice ThéveninAffiliated withDepartment of Radiology, Hôpital Cochin, Université Paris Descartes, AP-HP
  • , Sophie Piperno-NeumannAffiliated withDepartment of Oncology, Institut Curie
  • , Philippe AnractAffiliated withDepartment of Orthopaedic Surgery, Hôpital Cochin, Université Paris Descartes

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The use of allograft-prosthesis composites for reconstruction after bone tumor resection at the proximal femur has generated considerable interest since the mid1980s on the basis that their use would improve function and survival, and restore bone stock. Although functional improvement has been documented, it is unknown whether these composites survive long periods and whether they restore bone stock. We therefore determined long-term allograft-prosthesis composite survival, identified major complications that led to revision, and determined whether allograft bone stock could be spared at the time of revision. We also compared the radiographic appearance of allografts sterilized by gamma radiation and fresh-frozen allografts. We retrospectively reviewed 32 patients with bone malignancy in the proximal femur who underwent reconstruction with a cemented allograft-prosthesis composite. The allograft-prosthesis composite was a primary reconstruction for 23 patients and a revision procedure for nine. The minimum followup was 2 months (median, 68 months; range, 2–232 months). The cumulative incidence of revision for any reason was 14% at 5 years (95% confidence interval, 1%–28%) and 19% at 10 years (95% confidence interval, 3%–34%). Nine patients (28%) had revision of the reconstruction during followup; four of these patients had revision surgery for infection. Allografts sterilized by gamma radiation showed worse resorption than fresh-frozen allografts. Based on reported results, allograft-composite prostheses do not appear to improve survival compared with megaprostheses.

Level of Evidence: Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.